Teva wins European approval for biosimilar to Roche’s eye therapy Lucentis

Teva Canada"s facility in Markham, Ontario, Canada.

JHVEPhoto/iStock Editorial via Getty Images

  • Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced Monday that the European Commission authorized Ranivisio (ranibizumab), a biosimilar to Roche’s (OTCQX:RHHBY) (OTCQX:RHHBF) blockbuster eye therapy Lucentis.
  • The EU authorities have greenlighted Ranivisio for all five indications

Recommended For You

Comments (7)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.